Westpac Banking Corp Buys 3,305 Shares of Repligen Co. (NASDAQ:RGEN)

Westpac Banking Corp lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 17.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,725 shares of the biotechnology company's stock after purchasing an additional 3,305 shares during the quarter. Westpac Banking Corp's holdings in Repligen were worth $3,127,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of RGEN. Signaturefd LLC raised its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. bought a new stake in shares of Repligen during the fourth quarter worth $29,000. Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the third quarter worth $37,000. Quarry LP lifted its position in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 239 shares in the last quarter. Finally, UMB Bank n.a. boosted its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Shares of RGEN traded up $14.96 during midday trading on Wednesday, reaching $123.85. 1,251,254 shares of the stock were exchanged, compared to its average volume of 697,825. The stock's 50 day simple moving average is $144.76 and its 200 day simple moving average is $146.63. The company has a market cap of $6.95 billion, a P/E ratio of -242.84, a PEG ratio of 4.54 and a beta of 1.27. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Remove Ads

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. On average, sell-side analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

RGEN has been the topic of a number of research reports. Canaccord Genuity Group boosted their price target on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday, February 21st. Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, April 4th. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $178.64.

Insiders Place Their Bets

In other news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.